{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:31:24Z","timestamp":1787509884687,"version":"build-2736575974"},"reference-count":94,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T00:00:00Z","timestamp":1622937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Knowledge on hidradenitis suppurativa\/acne inversa (HS) is rapidly increasing. HS has a profound impact on patients and their family life. Several factors, such as comorbidities, unemployment and HS severity, make this impact even more severe. The most widely used instrument to measure this impact is the dermatology-specific DLQI. We also identified six HS-specific health-related quality of life (HRQoL) instruments. Of them, HIDRAdisk, HSIA, HiSQOL and HSQoL-24 are better validated but there is still lack of experience of its use. Several treatment methods showed positive effect on patients\u2019 HRQoL. Surgery remains a method with a substantial positive effect on HRQoL. Several studies confirming a positive effect of adalimumab on the HRQoL of patients with HS were published during the last three years. Data on the influence of several other biologics on HRQoL of HS patients are controversial or based on studies with a small number of patients.<\/jats:p>","DOI":"10.3390\/ijerph18116131","type":"journal-article","created":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T23:59:55Z","timestamp":1623023995000},"page":"6131","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["Quality of Life in Hidradenitis Suppurativa: An Update"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7275-4651","authenticated-orcid":false,"given":"Pavel V.","family":"Chernyshov","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Bogomolets National Medical University, 01601 Kiev, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-1646","authenticated-orcid":false,"given":"Andrew Y.","family":"Finlay","sequence":"additional","affiliation":[{"name":"Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5891-628X","authenticated-orcid":false,"given":"Lucia","family":"Tomas-Aragones","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of Zaragoza, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Poot","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Erasme, 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7624-3290","authenticated-orcid":false,"given":"Francesca","family":"Sampogna","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Unit, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5632-0351","authenticated-orcid":false,"given":"Servando E.","family":"Marron","sequence":"additional","affiliation":[{"name":"Aragon Psychodermatology Research Group (GAI + PD), Department of Dermatology, University Hospital Miguel Servet, 50009 Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5039-1324","authenticated-orcid":false,"given":"Sergey V.","family":"Zemskov","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Bogomolets National Medical University, 01601 Kiev, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0167-7617","authenticated-orcid":false,"given":"Damiano","family":"Abeni","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Unit, IDI-IRCCS, 00167 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thrasyvoulos","family":"Tzellos","sequence":"additional","affiliation":[{"name":"Department of Dermatology, NLSH University Hospital, 8092 Bod\u00f8, Norway"},{"name":"European Hidradenitis Suppurativa Foundation e.V., 06847 Dessau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-6342","authenticated-orcid":false,"given":"Jacek C.","family":"Szepietowski","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation e.V., 06847 Dessau, Germany"},{"name":"Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, 50-368 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1646-2608","authenticated-orcid":false,"given":"Christos C.","family":"Zouboulis","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation e.V., 06847 Dessau, Germany"},{"name":"Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences, 06847 Dessau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000431175","article-title":"Hidradenitis Suppurativa\/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation","volume":"231","author":"Zouboulis","year":"2015","journal-title":"Dermatology"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Jfri, A., Nassim, D., O\u2019Brien, E., Gulliver, W., Nikolakis, G., and Zouboulis, C.C. (2021). Prevalence of hidradenitis suppurativa: A systematic review and meta-regression study. JAMA Dermatol., in press.","DOI":"10.1001\/jamadermatol.2021.1677"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/jdv.15233","article-title":"Hidradenitis suppurativa\/acne inversa: A practical framework for treatment optimization\u2014systematic review and recommendations from the HS ALLIANCE working group","volume":"33","author":"Zouboulis","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/exd.14214","article-title":"What causes hidradenitis suppurativa ?\u201415 years after","volume":"29","author":"Zouboulis","year":"2020","journal-title":"Exp. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/jdv.16147","article-title":"Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa","volume":"34","author":"Zouboulis","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS 4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Zouboulis, C.C., Frew, J.W., Giamarellos-Bourboulis, E.J., Jemec, G.B.E., del Marmol, V., Marzano, A.V., Nikolakis, G., Sayed, C.J., Tzellos, T., and Wolk, K. (2021). Target molecules for future hidradenitis suppurativa treatment. Exp. Dermatol., online ahead of print.","DOI":"10.1111\/exd.14338"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjd.18173","article-title":"Ex Vivo human models of hidradenitis suppurativa\/acne inversa for laboratory research and drug screening","volume":"181","author":"Zouboulis","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000493342","article-title":"Standardized Photographic Documentation of Hidradenitis Suppurativa\/Acne Inversa","volume":"235","author":"Zouboulis","year":"2019","journal-title":"Dermatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1111\/jdv.15710","article-title":"Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: A multicentre study","volume":"33","author":"Martorell","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1111\/jdv.16496","article-title":"Color Doppler ultrasound: A standard of care in hidradenitis suppurativa","volume":"34","author":"Wortsman","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000495982","article-title":"Long-Wave Medical Infrared Thermography: A Clinical Biomarker of Inflammation in Hidradenitis Suppurativa\/Acne Inversa","volume":"235","author":"Zouboulis","year":"2019","journal-title":"Dermatology"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zouboulis, C.C. (2021). Pain Index: A new prospective hidradenitis suppurativa patient-reported outcome measure instrument. Br. J. Dermatol.","DOI":"10.1111\/bjd.19798"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jaad.2009.09.021","article-title":"Hidradenitis suppurativa markedly decreases quality of life and professional activity","volume":"62","author":"Matusiak","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/jdv.15519","article-title":"Quality of life measurement in hidradenitis suppurativa: Position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa","volume":"33","author":"Chernyshov","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Krajewski, P.K., Matusiak, \u0141., Von Stebut, E., Schultheis, M., Kirschner, U., Nikolakis, G., and Szepietowski, J.C. (2021). Quality-of-Life Impairment among Patients with Hidradenitis Suppurativa: A Cross-Sectional Study of 1795 Patients. Life, 11.","DOI":"10.3390\/life11010034"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/jdv.13985","article-title":"Why quality of life measurement is important in dermatology clinical practice","volume":"31","author":"Finlay","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/jdv.14585","article-title":"Quality of life measurement in acne. Position Paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa","volume":"32","author":"Chernyshov","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/jdv.14058","article-title":"Quality of life measurement in atopic dermatitis. Position paper of the European Academy of Dermatology and Venereology (EADV) Task Force on quality of life","volume":"31","author":"Chernyshov","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1111\/jdv.13154","article-title":"EADV Taskforce\u2019s recommendations on measurement of health-related quality of life in paediatric dermatology","volume":"29","author":"Chernyshov","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/jdv.12090","article-title":"Measurement of health-related quality of life in dermatological research and practice: Outcome of the EADV Taskforce on Quality of Life","volume":"27","author":"Prinsen","year":"2013","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/jdv.14288","article-title":"Measuring the impact of dermatological conditions on family and caregivers: A review of dermatology-specific instruments","volume":"31","author":"Sampogna","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/jdv.15048","article-title":"Which acne treatment has the best influence on health-related quality of life? Literature review by the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes","volume":"32","author":"Chernyshov","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/jdv.15487","article-title":"Quality of life measurement in skin cancer patients: Literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer","volume":"33","author":"Chernyshov","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1111\/jdv.16742","article-title":"Quality of life measurement in occupational skin diseases. Position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes and Occupational Skin Disease","volume":"34","author":"Chernyshov","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/jdv.16914","article-title":"Methods to improve quality of life, beyond medicines. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes","volume":"35","author":"Finlay","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/jdv.16720","article-title":"Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes on quality of life issues in dermatologic patients during the COVID-19 pandemic","volume":"34","author":"Chernyshov","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"546","DOI":"10.2340\/00015555-2650","article-title":"Quimp: A Word Meaning \u201cQuality of Life Impairment\u201d","volume":"97","author":"Finlay","year":"2017","journal-title":"Acta Derm. Venereol."},{"key":"ref_29","first-page":"e181","article-title":"Quimp (quality of life impairment): An addition to the quality of life lexicon","volume":"32","author":"Chernyshov","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/1203475416677721","article-title":"Development of a Quality-of-Life Measure for Hidradenitis Suppurativa","volume":"21","author":"Sisic","year":"2016","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jaad.2017.08.030","article-title":"Hidradenitis suppurativa burden of disease tool: Pilot testing of a disease-specific quality of life questionnaire","volume":"78","author":"Pinard","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/bjd.18692","article-title":"The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: Development and validation of a measure for clinical trials","volume":"183","author":"Kirby","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_33","first-page":"554","article-title":"Development and Preliminary Validation of the HSQoL-24 Tool to Assess Quality of Life in Patients with Hidradenitis Suppurativa","volume":"110","author":"Rull","year":"2019","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_34","first-page":"e24","article-title":"HIDRAdisk: An innovative visual tool to assess the burden of hidradenitis suppurativa","volume":"33","author":"Chiricozzi","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/09546634.2017.1341614","article-title":"Development and initial psychometric evaluation of patient-reported outcome questionnaires to evaluate the symptoms and impact of hidradenitis suppurativa","volume":"29","author":"Kimball","year":"2018","journal-title":"J. Dermatol. Treat."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/bjd.19344","article-title":"Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa","volume":"184","author":"Kirby","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.crohns.2008.02.002","article-title":"Efficacy of Infliximab treatment in patients with severe Fistulizing Hidradenitis Suppurativa","volume":"2","author":"Elkjaer","year":"2008","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","article-title":"Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial","volume":"80","author":"Vossen","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","first-page":"170","article-title":"Apremilast for the Treatment of Mild-to-Moderate Hidradenitis Suppurativa in a Prospective, Open-Label, Phase 2 Study","volume":"18","author":"Kerdel","year":"2019","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e14643","DOI":"10.1111\/dth.14643","article-title":"Real life data on the biopsychosocial effects of Adalimumab in the management of hidradenitis suppurativa: A multicenter cross sectional analysis and consideration of a multisystem monitoring approach to follow up","volume":"34","author":"Muralidharan","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/ced.14127","article-title":"Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab","volume":"45","author":"Caro","year":"2020","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/bjd.18983","article-title":"Evidence for a \u2018window of opportunity\u2019 in hidradenitis suppurativa treated with adalimumab: A retrospective, real-life multicentre cohort study","volume":"184","author":"Marzano","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/1346-8138.14997","article-title":"Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa","volume":"46","author":"Morita","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000503606","article-title":"Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa\/Acne Inversa","volume":"236","author":"Zouboulis","year":"2020","journal-title":"Dermatology"},{"key":"ref_46","first-page":"437","article-title":"Adalimumab versus Rifampicin Plus Clindamycin for the Treatment of Moderate to Severe Hidradenitis Suppurativa: A Retrospective Study","volume":"18","author":"Marasca","year":"2019","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/jdv.15821","article-title":"Age and gender influence on HIDRAdisk outcomes in adalimumab-treated hidradenitis suppurativa patients","volume":"33","author":"Fabbrocini","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000501075","article-title":"Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa","volume":"236","author":"Vilarrasa","year":"2020","journal-title":"Dermatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.17822","article-title":"Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa","volume":"181","author":"Prussick","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s40257-020-00537-9","article-title":"Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study","volume":"21","author":"Grimstad","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e13901","DOI":"10.1111\/dth.13901","article-title":"Intralesional ultrasound-guided combined treatment with triamcinolone plus lincomycin in hidradenitis suppurativa: A pilot study","volume":"33","author":"Fania","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1111\/jdv.15353","article-title":"Evaluation of medical and surgical treatments for hidradenitis suppurativa using real-life data from the Scandinavian registry (HISREG)","volume":"33","author":"Grimstad","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.anplas.2018.06.013","article-title":"Traitement radical de la maladie de Verneuil: Comparaison de l\u2019utilisation du derme artificiel et des lambeaux perforants p\u00e9dicul\u00e9s","volume":"64","author":"Gibrila","year":"2019","journal-title":"Annales de Chirurgie Plastique Esth\u00e9tique"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1111\/jdv.15706","article-title":"Surgical outcomes and the impact of major surgery on quality of life, activity impairment and sexual health in hidradenitis suppurativa patients: A prospective single centre study","volume":"33","author":"Prens","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Guart, J.A., Byers, V.V., Sasson, D.C., Bassiri-Tehrani, B., Ranzer, M., and Purnell, C. (2021). Postoperative Quality of Life in Patients with Hidradenitis Suppurativa Utilizing the Hidradenitis Suppurativa Burden of Disease Tool. Cureus, 13.","DOI":"10.7759\/cureus.13172"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/SAP.0000000000002482","article-title":"Wide Local Excisions and Pedicled Perforator Flaps in Hidradenitis Suppurativa","volume":"86","author":"Marchesi","year":"2021","journal-title":"Ann. Plast. Surg."},{"key":"ref_57","first-page":"1","article-title":"Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF)","volume":"30","author":"Wilden","year":"2019","journal-title":"J. Dermatol. Treat."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaad.2018.11.035","article-title":"Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations","volume":"80","author":"Caro","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/ced.14388","article-title":"Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasonography evaluation","volume":"46","author":"Caro","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1111\/jdv.16255","article-title":"Psychosocial burden of Hidradenitis Suppurativa patients\u2019 partners","volume":"34","author":"Matusiak","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1111\/jdv.16319","article-title":"Quality of life in people living with patients suffering from hidradenitis suppurativa","volume":"34","author":"Marasca","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Ramos-Alejos-Pita, C., Arias-Santiago, S., and Molina-Leyva, A. (2020). Quality of Life in Cohabitants of Patients with Hidradenitis Suppurativa: A Cross-sectional Study. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17166000"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jaad.2020.09.072","article-title":"Quality of life in hidradenitis suppurativa: A cross-sectional study of a pediatric population","volume":"84","author":"McAndrew","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/jdv.16132","article-title":"Baseline patient-reported outcomes from UNITE: An observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice","volume":"34","author":"Kimball","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_65","first-page":"427","article-title":"Factors affecting quality of life in patients with hidradenitis suppurativa","volume":"312","author":"Holm","year":"2019","journal-title":"Arch. Dermatol. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/ijd.14706","article-title":"Work productivity and activity impairment in patients with hidradenitis suppurativa: A cross-sectional study","volume":"59","author":"Yao","year":"2019","journal-title":"Int. J. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jaad.2020.07.115","article-title":"Impact of hidradenitis suppurativa on work productivity and associated risk factors","volume":"84","author":"Prens","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2019.06.1301","article-title":"Evaluating patients\u2019 unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project","volume":"82","author":"Garg","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"13030\/qt4rm8w7kn","DOI":"10.5070\/D3269050156","article-title":"Physical symptoms and psychosocial problems associated with hidradenitis suppurativa: Correlation with Hurley stage","volume":"26","author":"McKenzie","year":"2020","journal-title":"Dermatol. Online J."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/bjd.17928","article-title":"Even mild hidradenitis suppurativa impairs quality of life","volume":"181","author":"Senthilnathan","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/bjd.17508","article-title":"Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment","volume":"180","author":"Rondags","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00403-020-02063-4","article-title":"Age-specific physical and mental health status in Italian patients with hidradenitis suppurativa: A comparison with the general population","volume":"313","author":"Sampogna","year":"2021","journal-title":"Arch. Dermatol. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bjd.17123","article-title":"To what extent do disease severity and illness perceptions explain depression, anxiety and quality of life in hidradenitis suppurativa?","volume":"180","author":"Blanco","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000502139","article-title":"Pruritus and Malodour in Patients with Hidradenitis Suppurativa: Impact on Quality of Life and Clinical Features Associated with Symptom Severity","volume":"236","year":"2020","journal-title":"Dermatology"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Akoglu, G., Yildiz, I., Karaismailo\u011flu, E., and Esme, P. (2021). Disease severity and poor mental health are the main predictors of stigmatization in patients with hidradenitis suppurativa. Dermatol. Ther., e14910.","DOI":"10.1111\/dth.14910"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/1346-8138.14722","article-title":"Hidradenitis suppurativa of the nape: Description of an atypical phenotype related to severe early-onset disease in men","volume":"46","author":"Ribera","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"676241","DOI":"10.3389\/fmed.2021.676241","article-title":"Features Associated With Quality of Life Impairment in Hidradenitis Suppurativa Patients","volume":"8","author":"Tsaousi","year":"2021","journal-title":"Front. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000503319","article-title":"Alexithymia, Psychological Distress, and Social Impairment in Patients with Hidradenitis Suppurativa","volume":"237","author":"Quinto","year":"2021","journal-title":"Dermatology"},{"key":"ref_79","first-page":"adv00319","article-title":"Correlation between Depression, Quality of Life and Clinical Severity in Patients with Hidradenitis Suppurativa","volume":"100","author":"Sampogna","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000496604","article-title":"The Broad-Spectrum Impact of Hidradenitis Suppurativa on Quality of Life: A Comparison with Psoriasis","volume":"235","author":"Sampogna","year":"2019","journal-title":"Dermatology"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1001\/jamadermatol.2019.2610","article-title":"Incidence of Long-term Opioid Use Among Opioid-Naive Patients With Hidradenitis Suppurativa in the United States","volume":"155","author":"Reddy","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"adv00107-6","DOI":"10.2340\/00015555-3464","article-title":"Body Image Quality of Life in Patients with Hidradenitis Suppurativa Compared with Other Dermatological Disorders","volume":"100","author":"Andersen","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000496923","article-title":"The Evolution of Quality of Life Assessment and Use in Dermatology","volume":"235","author":"Chernyshov","year":"2019","journal-title":"Dermatology"},{"key":"ref_84","first-page":"e722","article-title":"Physician severity scores correlate poorly with health-related quality of life in patients with Hidradenitis Suppurativa","volume":"34","author":"Prens","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1111\/jdv.16921","article-title":"Selection process of measures for core outcome set should utilize the highest methodology level and should be maximally free of bias. Comment on \u2018IDQoL, CDLQI and the 45-item CADIS received a sufficient content validity rating during the HOME VII meeting in Japan: A group discussion study\u2019","volume":"35","author":"Chernyshov","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1038\/sj.jid.5700875","article-title":"Cross-Cultural Inequivalence of Dermatology-Specific Health-Related Quality of Life Instruments in Psoriasis Patients","volume":"127","author":"Nijsten","year":"2007","journal-title":"J. Investig. Dermatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1468-3083.2010.03945.x","article-title":"Comparative study of the quality of life of children with atopic dermatitis from Ukraine and the Czech Republic","volume":"25","author":"Chernyshov","year":"2011","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1111\/jdv.15229","article-title":"Creation and pilot test results of the dermatology-specific proxy instrument: The Infants and Toddlers Dermatology Quality of Life","volume":"32","author":"Chernyshov","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/jdv.15496","article-title":"Validation of the dermatology-specific proxy instrument the Infants and Toddlers Dermatology Quality of Life","volume":"33","author":"Chernyshov","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/jdv.15337","article-title":"Epidermolysis bullosa-specific module of the Infants and Toddlers Dermatology Quality of Life (InToDermQoL) questionnaire","volume":"33","author":"Chernyshov","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e14128","DOI":"10.1111\/dth.14128","article-title":"Initial validation of the epidermolysis bullosa-specific module of the Infants and Toddlers Dermatology Quality of Life questionnaire","volume":"33","author":"Chernyshov","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_92","first-page":"277","article-title":"Dermatological quality of life instruments in children","volume":"148","author":"Chernyshov","year":"2013","journal-title":"G. Ital. Dermatol. Venereol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-4632.2011.04997.x","article-title":"Gender differences in health-related and family quality of life in young children with atopic dermatitis","volume":"51","author":"Chernyshov","year":"2012","journal-title":"Int. J. Dermatol."},{"key":"ref_94","first-page":"19","article-title":"Gender Differences in Self-assessed Health-related Quality of Life in Children with Atopic Dermatitis","volume":"9","author":"Chernyshov","year":"2016","journal-title":"J. Clin. Aesthetic Dermatol."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/11\/6131\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:11:27Z","timestamp":1760163087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/11\/6131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,6]]},"references-count":94,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["ijerph18116131"],"URL":"https:\/\/doi.org\/10.3390\/ijerph18116131","relation":{},"ISSN":["1660-4601"],"issn-type":[{"value":"1660-4601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,6]]}}}